Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Acute Myeloid Leukemia With FLT3/ITD Mutation”

56 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 56 results

Early research (Phase 1)Ended earlyNCT03552029
What this trial is testing

Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myeloid Leukemia
Daiichi Sankyo 10
Not applicableNo Longer AvailableNCT02624570
What this trial is testing

Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy

Who this might be right for
Acute Myeloid Leukemia (AML) WithFLT3 Mutation, Internal Tandem Duplication (ITD) or Tyrosine Kinase Domain (TKD)
Novartis Pharmaceuticals
Not applicableNo Longer AvailableNCT03746912
What this trial is testing

Expanded Treatment Protocol for Adults With FLT3-ITD Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) to Receive Quizartinib

Who this might be right for
Acute Myeloid Leukemia With Gene Mutations
Daiichi Sankyo
Testing effectiveness (Phase 2)Study completedNCT00989261
What this trial is testing

Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myeloid Leukemia
Daiichi Sankyo 333
Testing effectiveness (Phase 2)Study completedNCT02984995
What this trial is testing

Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation

Who this might be right for
Leukemia, Myeloid, Acute
Daiichi Sankyo Co., Ltd. 37
Testing effectiveness (Phase 2)Ended earlyNCT04209725
What this trial is testing

CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia

Who this might be right for
Leukemia, Myeloid, Acute
SCRI Development Innovations, LLC 1
Large-scale testing (Phase 3)Study completedNCT02997202
What this trial is testing

A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myeloid Leukemia
Astellas Pharma Global Development, Inc. 356
Not applicableStudy completedNCT05193448
What this trial is testing

A Non-interventional Ambispective Real-world Cohort of rEfractory and reLapsed (R/R) FLT3 Mutated Acute MyEloid Leukemia (AML) Patients Treated With Gilteritinib in FrANCE

Who this might be right for
Refractory AMLRelapsed Adult AMLFLT3-TKD Mutation+1 more
French Innovative Leukemia Organisation 177
Early research (Phase 1)Ended earlyNCT04496999
What this trial is testing

HDM201 and Midostaurin (HDMM) in Relapsed/Refractory AML With FLT3mut and TP53wt.

Who this might be right for
AML, Adult
Insel Gruppe AG, University Hospital Bern 2
Testing effectiveness (Phase 2)Study completedNCT01477606
What this trial is testing

Protocol in Acute Myeloid Leukemia With FLT3-ITD

Who this might be right for
Acute Myeloid Leukemia
University of Ulm 451
Testing effectiveness (Phase 2)Study completedNCT02728050
What this trial is testing

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Who this might be right for
Acute Biphenotypic LeukemiaAcute Myeloid Leukemiade Novo Myelodysplastic Syndrome+2 more
University of Washington 84
Early research (Phase 1)Ended earlyNCT04477291
What this trial is testing

CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Syndromes
Aptose Biosciences Inc. 45
Testing effectiveness (Phase 2)Study completedNCT01565668
What this trial is testing

Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Leukemia, Myeloid, Acute
Daiichi Sankyo 76
Large-scale testing (Phase 3)UnknownNCT04174612
What this trial is testing

AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance

Who this might be right for
Acute Myeloid Leukemia With FLT3/ITD Mutation
Gruppo Italiano Malattie EMatologiche dell'Adulto 172
Testing effectiveness (Phase 2)Looking for participantsNCT06022003
What this trial is testing

Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia

Who this might be right for
AML, AdultRefractory AMLRelapsed Adult AML+2 more
French Innovative Leukemia Organisation 33
Testing effectiveness (Phase 2)Ended earlyNCT03735875
What this trial is testing

Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia With FLT3/ITD MutationRecurrent Acute Myeloid LeukemiaRefractory Acute Leukemia
M.D. Anderson Cancer Center 8
Testing effectiveness (Phase 2)Looking for participantsNCT04278768
What this trial is testing

Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Who this might be right for
Acute Myelogenous LeukemiaMyelodysplastic Syndrome
Curis, Inc. 366
Testing effectiveness (Phase 2)Study completedNCT01349049
What this trial is testing

Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myeloid Leukemia
Daiichi Sankyo 90
Testing effectiveness (Phase 2)Ended earlyNCT01028716
What this trial is testing

Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Who this might be right for
Acute Biphenotypic LeukemiaAcute Erythroid Leukemia in RemissionAcute Leukemia in Remission+27 more
Fred Hutchinson Cancer Center 46
Early research (Phase 1)Study completedNCT01578109
What this trial is testing

Sorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia With FLT3/ITD Mutation
National Cancer Institute (NCI) 51
Load More Results